Supplementary Figure S9 from Combining Brigatinib with mTOR Inhibition to Effectively Treat NF2-SWN–Associated and Sporadic NF2-Deficient Meningiomas
Abstract
Figure S9. Ingenuity Pathway analysis indicated that the activities of several upstream regulators important for meningioma growth were significantly altered in AG-NF2-Men cells treated with the brigatinib+INK128 combination.
Fields of Study & Subjects
Meningioma and schwannoma management
Neurofibromatosis and Schwannoma Cases
PI3K/AKT/mTOR signaling in cancer
Publication details
- Publication date
- 27 January 2026